Etanercept liposomal - BetterLife Pharma
Alternative Names: NK-002Latest Information Update: 17 Nov 2021
Price :
$50 *
At a glance
- Originator Neurokine Pharmaceuticals
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 05 Dec 2019 Pivot Pharmaceuticals is now called BetterLife Pharma
- 16 Jul 2016 No recent reports of development identified for research development in Alzheimer's-disease in Canada (Liposomal)
- 02 May 2011 Early research in Alzheimer's disease in Canada (unspecified route)